NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD
18.74
+1.08 (+6.12%)
The current stock price of NGNE is 18.74 USD. In the past month the price increased by 24.93%. In the past year, price decreased by -50.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.07 | 327.88B | ||
AMGN | AMGEN INC | 13.66 | 152.46B | ||
GILD | GILEAD SCIENCES INC | 14.36 | 138.21B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.81B | ||
REGN | REGENERON PHARMACEUTICALS | 13.66 | 65.36B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.19B | ||
ARGX | ARGENX SE - ADR | 98.97 | 35.47B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.31 | 26.67B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.10B | ||
NTRA | NATERA INC | N/A | 21.58B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.47B | ||
BIIB | BIOGEN INC | 8.39 | 19.45B |
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 107
Phone: 18772375020
The current stock price of NGNE is 18.74 USD. The price increased by 6.12% in the last trading session.
The exchange symbol of NEUROGENE INC is NGNE and it is listed on the Nasdaq exchange.
NGNE stock is listed on the Nasdaq exchange.
13 analysts have analysed NGNE and the average price target is 45.29 USD. This implies a price increase of 141.66% is expected in the next year compared to the current price of 18.74. Check the NEUROGENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEUROGENE INC (NGNE) has a market capitalization of 267.23M USD. This makes NGNE a Micro Cap stock.
NEUROGENE INC (NGNE) currently has 107 employees.
NEUROGENE INC (NGNE) has a support level at 17.28 and a resistance level at 19.08. Check the full technical report for a detailed analysis of NGNE support and resistance levels.
The Revenue of NEUROGENE INC (NGNE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the NGNE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NGNE does not pay a dividend.
NEUROGENE INC (NGNE) will report earnings on 2025-08-07, before the market open.
NEUROGENE INC (NGNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.35).
The outstanding short interest for NEUROGENE INC (NGNE) is 23.18% of its float. Check the ownership tab for more information on the NGNE short interest.
ChartMill assigns a technical rating of 4 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE is a bad performer in the overall market: 83.81% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NGNE. The financial health of NGNE is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.35. The EPS decreased by -51.24% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.38% | ||
ROE | -24.21% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 88% to NGNE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -13.67% and a revenue growth -100% for NGNE